Aduro Biotech, Dimitry Nuyten
Aduro Biotech moves to bring in Dimitry Nuyten as its CMO, arriving at the company after nearly six years as immune-oncology clinical development leader at Pfizer.
Aduro is working on developing treatments that harness the body’s immune system, particularly looking at stimulator of interferon genes (STING) and ‘a proliferation inducing ligand’ (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases.
The biotech currently has five treatments in Phase I – partnering with Novartis, Eli Lilly, and Merck (known as MSD in Europe) on these drug candidates.
Stephen Isaacs, CEO of Aduro, said, “We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy.”
At the beginning of the year, the biotech announced a ‘strategic reset’ to focus its efforts on its candidates using the STING and APRIL pathways. The action saw its workforce cut by 37%, with the resources going instead to its lead programs in development.